Xenpozyme, olipudase alfa-rpcp
Named-patient access overview. Xenpozyme is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Xenpozyme
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Xenpozyme
Xenpozyme (olipudase alfa-rpcp) is manufactured by Sanofi and indicated for Acid sphingomyelinase deficiency (ASMD, non-CNS manifestations). It is an enzyme replacement therapy (IV infusion) approved by the US FDA in 2022 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Xenpozyme
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Xenpozyme for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Xenpozyme is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Xenpozyme for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Xenpozyme is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Xenpozyme
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.